옵션 체인은 다양한 행사가격과 만기일에 대한 Royalty Pharma의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Royalty Pharma에 대한 시장 심리를 평가합니다..

Royalty Pharma (NASDAQ:RPRX) 주식, 옵션 체인

Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Biotech

Earnings

Equities

News

Markets

Movers

AMGN

ARWR

RPRX

목요일 시장 마감 후 암젠(NASDAQ:AMGN)은 1분기 재무 결과를 발표했다. 여기에는 몇 가지 핵심 내용을 보자. 세부 사항 (The Details): 암젠은 분기별 이익을 주당 3.96달러로 보고했는데, 이는 분석가 컨센서스인 3.87달러보다 2.33% 높았다. 이 회사는 호라이즌(Horizon) 인수로 인한 운영 및 이자 비용 증가로 인해 주당순이익(EPS)이 1% 감소했으며 매출 증가로 부분적으로 상쇄되었다고 밝혔다.

암젠: 예상보다 좋은 1분기 실적 및 5,000만 달러의 마일스톤 지급금 수입에 주가 급등

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma PLC

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

Dividends

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.93 by 11.83 percent. The company reported quarterly sales of $565.00 million which missed the analyst consensus estimate of $696.10 million by 18.83 percent. This is a 5.41 percent increase over sales of $536.00 million the same period last year.

Earnings Beats

Royalty Pharma Q3 2024 Adj EPS $1.04 Beats $0.93 Estimate

Guidance

Royalty Pharma Raises Full Year 2024 Guidance For Portfolio Receipts From $2.70B - $2.775B To $2.75B - $2.80B

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly sales of $565.00 million which missed the analyst consensus estimate of $696.10 million by 18.83 percent. This is a 5.41 percent increase over sales of $536.00 million the same period last year.

Earnings Misses

Royalty Pharma Q3 Sales $565.00M May Not Be Comparable To $696.10M Estimate

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Royalty Pharma to report an earnings per share (EPS) of $0.93.
Investors in Royalty Pharma are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 0.42% increase in the share price on the subsequent day.
Here's a look at Royalty Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.99</td>
<td>0.99</td>
<td>0.99</td>
<td>0.77</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.96</td>
<td>0.98</td>
<td>1.15</td>
<td>0.79</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730815375_0.png" alt="eps graph" />
<h3>Insights Shared by Analysts on Royalty Pharma</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Royalty Pharma.
With 2 analyst ratings, Royalty Pharma has a consensus rating of Buy. The average one-year price target is $45.5, indicating a potential 67.28% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Intra-Cellular Therapies, Jazz Pharmaceuticals and Elanco Animal Health, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Intra-Cellular Therapies received a Outperform consensus from analysts, with an average 1-year price target of $100.93, implying a potential 271.07% upside.</li>
<li>As per analysts' assessments, Jazz Pharmaceuticals is favoring an Outperform trajectory, with an average 1-year price target of $180.2, suggesting a potential 562.5% upside.</li>
<li>Elanco Animal Health is maintaining an Outperform status according to analysts, with an average 1-year price target of $19.0, indicating a potential 30.15% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Intra-Cellular Therapies, Jazz Pharmaceuticals and Elanco Animal Health are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catalent</td>
<td>Neutral</td>
<td>23.32%</td>
<td>$384M</td>
<td>0.64%</td>
</tr>
<tr>
<td>Intra-Cellular Therapies</td>
<td>Outperform</td>
<td>39.23%</td>
<td>$159.85M</td>
<td>-2.30%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>Outperform</td>
<td>6.95%</td>
<td>$913.92M</td>
<td>4.52%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Outperform</td>
<td>12.02%</td>
<td>$689M</td>
<td>-0.83%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Royalty Pharma ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>About Royalty Pharma</h3>
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson &amp; Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
<h3>Royalty Pharma: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Royalty Pharma's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -0.17%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Royalty Pharma's net margin excels beyond industry benchmarks, reaching 18.99%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.57%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Royalty Pharma's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.6%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.17.
<a href="https://www.benzinga.com/quote/RPRX/earnings">To track all earnings releases for Royalty Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Royalty Pharma's Quarterly Earnings

General

SNDX

Royalty Pharma Enters $350M Royalty Funding Agreement With Syndax Pharmaceuticals To Support Launches And Development Of Niktimvo And Revumenib, Boosting Proforma Cash To Nearly $800M

Citigroup analyst Andrew Baum maintains Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) with a Buy and lowers the price target from $60 to $40.

Citigroup Maintains Buy on Royalty Pharma, Lowers Price Target to $40

Royalty Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NYSE">RPRX</a>) short percent of float has fallen 3.24% since its last report. The company recently reported that it has 14.19 million shares sold short, which is 3.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Royalty Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728413113_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Royalty Pharma has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Royalty Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Royalty Pharma's peer group average for short interest as a percentage of float is 4.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Royalty Pharma's Recent Short Interest

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

EXAS

ILMN

MRNA

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

Tuesday, Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) reported second-quarter sales of $38.76 million (35.9 million euros), <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">missing the consensus of $92.7 million</a>, down from 47.4 million euros reported a year ago.
Results in the quarter were primarily impacted by a negative adjustment to prior periods' estimates and assumptions for sales deductions of 27.1 million euros, where 19.5 million euros and 7.6 million euros were attributable to the three months ended&nbsp;March 31, 2024, and periods before <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40697101/ascendis-pharma-reports-second-quarter-2024-financial-results" rel="noreferrer noopener">January 1, 2024, respectively</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40316248/ascendis-hypoparathyroidism-drug-scores-fda-approval-as-first-and-only-treatment-replacing-takeda" rel="noreferrer noopener">Ascendis&#8217; Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda&#8217;s Drug Discontinued Due To Supply Issues</a>.
The company reported an EPS loss of $(2.06) or (1.91 euros), missing the consensus loss of $(1.56) and down from a loss of 2.16 euros a year ago.
Skytrofa, indicated as a once-weekly pediatric growth hormone treatment, generated revenue of 26 million euros, a 27%&nbsp;decrease&nbsp;year over year. The 134% year over year volume growth was offset by the cost associated with broader market access.
Recently approved hypoparathyroidism drug Yorvipath&#8217;s revenue totaled €5.2 million, reflecting the first full quarter of commercial launch in&nbsp;Germany&nbsp;and&nbsp;Austria&nbsp;as well as initial revenue in International Markets. Initial revenue in&nbsp;France&nbsp;is expected to start in the fourth quarter of 2024.
Guidance: Ascendis Pharma has lowered its fiscal year 2024 sales guidance for Skytrofa to 220 million euros &#8211; 240 million euros from <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38596710/ascendis-pharma-reports-first-quarter-2024-financial-results" rel="noreferrer noopener">prior guidance of</a> 320 million euros to 340 million euros.
Concurrently, the company entered into a capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath with Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>).
Under the terms of the agreement, Ascendis receives an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of Yorvipath. The royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.0x or 1.65x if Royalty Pharma receives royalties in that amount by <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40697339/royalty-pharma-and-ascendis-pharma-enter-into-150-million-royalty-funding-agreement" rel="noreferrer noopener">December 31, 2029</a>.
Price Action: ASND stock is down 15% at $114.50 during the premarket session at last check Wednesday.
Photo via Shutterstock
Read Next
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40705415/dollar-tree-q2-earnings-revenue-and-eps-miss-cuts-annual-forecasts-as-customers-feel-macro-pressure" target="_blank" rel="noreferrer noopener">Dollar Tree Q2 Earnings: Revenue And EPS Miss, Cuts Annual Forecasts As Customers Feel Macro Pressure On Spending, Stock Tumbles</a>.</li>
</ul>

Health Care

ASND

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut

Contracts

Ascendis Pharma Subsidiary Enters $150M Capped Synthetic Royalty Funding Agreement With Royalty Pharma Based On US Net Sales Of YORVIPATH

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Ally Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>).
On July 17, Ally Financial posted stronger-than-expected<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39847452/ally-financial-analyst-sees-consistent-margin-expansion-ahead-q2-results-breakdown"> quarterly earnings results.</a>
Cramer said he is going to hold off from recommending Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>). &#8220;It's kind of like the long knives are out for those guys right now,&#8221; he added.
On Aug. 15, Wells Fargo analyst Michael Turrin downgraded the rating for Snowflake from Overweight to Equal-Weight and lowered the price target from $200 to $130.
When asked about Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), he said, &#8220;I always thought there was going to be more to this stock than there has been. It's really been a bit of a bust.&#8221;
On Aug. 8, Royalty Pharma reported worse-than-expected second-quarter financial results. The company reported quarterly earnings of 96 cents per share which missed the analyst consensus estimate of 99 cents per share. The company reported quarterly sales of $537.00 million which missed the analyst consensus estimate of $628.26 million.
Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) is a &#8220;very overvalued situation, principally because of the fact that it's never made any money. But it is another play on crypto. If you like crypto, buy crypto.&#8221;
On Aug. 14, Core Scientific announced that it increased its offering of convertible senior notes from $350 million to $400 million. The company has also given initial purchasers the option to buy up to an extra $60 million in notes.
Price Action:
<ul>
<li>Snowflake shares fell 0.2% to settle at $127.05 on Thursday.</li>
<li>Royalty Pharma shares rose 2.9% to close at $27.41.</li>
<li>Core Scientific shares gained 5.2% to settle at $9.26 on Thursday.</li>
<li>Ally Financial shares gained 1.3% to close at $41.61.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40394036/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></li>
</ul>

Long Ideas

Media

ALLY

Core Scientific, Inc. - Class A Common Stock

CORZ

SNOW

Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'

Goldman Sachs analyst Chris Shibutani maintains Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) with a Buy and raises the price target from $50 to $51.

Goldman Sachs Maintains Buy on Royalty Pharma, Raises Price Target to $51

Royalty Pharma shares are trading lower after the company reported worse-than-expected Q2 financial results.

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly earnings of $0.96 per share which missed the analyst consensus estimate of $0.99 by 3.03 percent. This is a 14.29 percent increase over earnings of $0.84 per share from the same period last year. The company reported quarterly sales of $537.00 million which missed the analyst consensus estimate of $628.26 million by 14.53 percent. This is a 0.19 percent decrease over sales of $538.00 million the same period last year.

Royalty Pharma Q2 Adj $0.96 Misses $0.99 Estimate, Sales $537.00M Miss $628.26M Estimate

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) with a Overweight and raises the price target from $48 to $51.

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $51

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments">high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings </a>page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.06%</li>
<li>B of A Securities analyst Geoff Meacham maintained a Buy rating and cut the price target from $40 to $38 on April 12. This analyst has an accuracy rate of 64%.</li>
<li>JP Morgan analyst Chris Schott maintained an Overweight rating and slashed the price target from $45 to $42 on Feb. 20. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On June 3, Royalty Pharma priced offering of $1.5 billion of senior unsecured notes.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent061224&amp;t=be2bearmibe3na1">latest Royalty Pharma news</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent061224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="678" height="770" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/12045644/Screenshot-2024-06-12-at-2.26.38-PM.png" alt="" class="wp-image-383841" style="width:450px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/12045644/Screenshot-2024-06-12-at-2.26.38-PM.png 678w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/12045644/Screenshot-2024-06-12-at-2.26.38-PM-264x300.png 264w" sizes="(max-width: 678px) 100vw, 678px" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.38%</li>
<li>Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $215 on May 6. This analyst has an accuracy rate of 68%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $168 to $167 on April 17. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: Johnson &amp; Johnson is scheduled to host a conference call for investors on Wednesday, July 17 to review second-quarter results.</li>
<li><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent061224&amp;t=be2bearmibe3na1">Benzinga Pro's charting tool</a> helped identify the trend in Johnson &amp; Johnson's stock.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent061224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="688" height="750" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/12045719/Screenshot-2024-06-12-at-2.27.14-PM.png" alt="" class="wp-image-383842" style="width:467px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/12045719/Screenshot-2024-06-12-at-2.27.14-PM.png 688w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/12045719/Screenshot-2024-06-12-at-2.27.14-PM-275x300.png 275w" sizes="(max-width: 688px) 100vw, 688px" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.42%</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and increased the price target from $102 to $105 on May 24. This analyst has an accuracy rate of 71%.</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and cut the price target from $90 to $88 on May 24. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Medtronic, last week, initiated a recall for some versions of its StealthStation S8 application.</li>
<li>Benzinga Pro's signals feature notified of a potential <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent061224&amp;t=be2bearmibe3na1">breakout in Medtronic's shares</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent061224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="665" height="755" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/12045827/Screenshot-2024-06-12-at-2.28.22-PM.png" alt="" class="wp-image-383843" style="width:469px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/12045827/Screenshot-2024-06-12-at-2.28.22-PM.png 665w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/12045827/Screenshot-2024-06-12-at-2.28.22-PM-264x300.png 264w" sizes="(max-width: 665px) 100vw, 665px" /></a></figure>
Check This Out: <a href="https://www.youtube.com/watch?v=pVF0O2lsEH4">How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pr</a>o

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

The offering is expected to close on June 10, 2024.&nbsp;Royalty Pharma intends to use the net proceeds from the Notes for general corporate purposes.

Offerings

Royalty Pharma Prices Offering Of $1.5B Of Senior Unsecured Notes

UBS analyst Ashwani Verma downgrades Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) from Buy to Neutral and announces $28 price target.

Downgrades

UBS Downgrades Royalty Pharma to Neutral, Announces $28 Price Target

Tuesday,&nbsp;Agios Pharmaceuticals&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) agreed to&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g39034943/agios-announces-905-million-purchase-agreement-for-vorasidenib-royalty" rel="noreferrer noopener">sell its rights</a>&nbsp;to its 15% royalty on potential U.S. net sales of&nbsp;Servier&#8217;s&nbsp;vorasidenib&nbsp;to&nbsp;Royalty Pharma Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>).&nbsp;
Under the terms of the agreement, Agios will receive an upfront payment of $905 million upon FDA approval of&nbsp;vorasidenib, and Royalty Pharma will receive the entirety of the 15% royalty on annual U.S. net sales of&nbsp;vorasidenib&nbsp;up to $1 billion and a 12% royalty on annual U.S. net sales greater than $1 billion.&nbsp;
Agios will retain a 3% royalty on annual U.S. net sales over&nbsp;$1 billion.
Vorasidenib is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes for IDH-mutant diffuse glioma.&nbsp;
IDH mutant gliomas are&nbsp;the most common adult, malignant primary brain tumors diagnosed in patients younger than 50.
In 2021, Agios&nbsp;completed the&nbsp;<a target="_blank" href="https://investor.agios.com/news-releases/news-release-details/agios-announces-closing-oncology-business-sale-servier" rel="noreferrer noopener">sale</a>&nbsp;of its oncology portfolio – including&nbsp;vorasidenib&nbsp;– to Servier.&nbsp;
As part of that divestiture, Agios is owed a milestone payment of&nbsp;$200 million&nbsp;upon vorasidenib&#8217;s approval by the FDA and a 15% royalty on U.S. net sales of&nbsp;vorasidenib.&nbsp;
Agios continues to retain the right to the approval milestone from Servier.&nbsp;Servier&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=WmFHv3fOBetDObvPv98dFcI0TdPQMfkZGZsBOQn2Y9FSHwqIXnjqd6AnfnHshuuGzJh2lan9SMLrrEbFUFRtzebZDHQErRMNYYZRRS7Zc14ddrxKbYh5kqct5tBvkBMM" rel="noreferrer noopener">announced</a>&nbsp;that the FDA has designated&nbsp;a&nbsp;Prescription Drug User Fee Act (PDUFA)&nbsp;action date&nbsp;of August 20.
Earlier this year, Agios Pharmaceuticals said the Phase 3 ENERGIZE study of&nbsp;mitapivat&nbsp;in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36468800/why-is-blood-disorder-focused-agios-pharmaceuticals-stock-trading-higher-today" rel="noreferrer noopener">endpoint of hemoglobin response</a>.&nbsp;
Statistical significance was also achieved&nbsp;for both&nbsp;key&nbsp;secondary endpoints associated with a change from baseline in FACIT-Fatigue Score and hemoglobin concentration.
Price Action: AGIO shares are up 20.7% at $38.03 at last check Tuesday.
Photo via Shutterstock

Asset Sales

AGIO

Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?

Royalty Pharma (RPRX) announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation's (GERN) RYTELO for $125 million in cas...

Royalty Pharma to acquire royalty interest in Geron's RYTELO for $125M

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Royalty Pharma (RPRX – Research Report), with a price targ...

Morgan Stanley Keeps Their Buy Rating on Royalty Pharma (RPRX)

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Royalty Pharma: Massive Opportunity Ahead

Dividend Champion, Contender, And Challenger Highlights: Week Of November 10

In a report released on November 7, Geoff Meacham from Citi maintained a Buy rating on Royalty Pharma (RPRX – Research Report). The company's share...

Citi Keeps Their Buy Rating on Royalty Pharma (RPRX)

This week, several dividend stocks are trading close to their 52-week lows. Here is a list of ten such stocks that are also reaching their ex-divid...

Ex-Dividend Date Nearing for These 10 Stocks – Week of November 11, 2024

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +

In a report released yesterday, Charlie CY Yang from Bank of America Securities reiterated a Buy rating on Royalty Pharma (RPRX – Research Report),...

Strong Buy Rating for Royalty Pharma: Robust Revenue Growth and Promising Pipeline

BofA analyst Charlie Yang raised the firm's price target on Royalty Pharma (RPRX) to $39 from $38 and keeps a Buy rating on the shares. The firm is...

Royalty Pharma price target raised to $39 from $38 at BofA

AAPL

AGCO

ALKS

ALSN

APLS

ARTNA

BOKF

BORT

CAAP

CARR

CASY

CCOI

CGNX

CNOB

COST

CRBP

CTAS

CTRA

DERM

DGICA

DGICB

EBMT

EFSI

ELAB

EQIX

EVRG

EWBC

FANG

FCFS

FDBC

FMBH

FREY

GCBC

GERN

GWRS

HESM

HOMB

HRZN

HTBI

HWKN

IBCP

IOSP

KLAC

LANC

LARK

MAIN

MDRX

MPLX

MSBI

MSCI

MSEX

MTRN

NKTR

NXST

ORRF

OTIS

OTTR

OXSQ

PEBO

POOL

REYN

RUSHA

SBAC

SBUX

SIGI

SMBC

SPFI

SRCE

TAIT

TALO

TKPHF

TSBK

URGN

UTMD

VALU

VCTR

VKTX

VRCA

VRNA

VRTS

WABC

WING

WTRG

ZION

Press Releases

Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference

Financing

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Royalty Pharma Declares Fourth Quarter 2024 Dividend

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo

Royalty Pharma Reports Third Quarter 2024 Results

Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Comments

Royalty Pharma

Royalty Pharma (RPRX) 옵션

Royalty Pharma (NASDAQ:RPRX) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌